Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Caribou Biosciences (CRBU) Revenue (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Revenue for 6 consecutive years, with $2.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Revenue rose 8.6% to $2.2 million in Q3 2025 year-over-year; TTM through Dec 2025 was $7.2 million, a 27.78% decrease, with the full-year FY2024 number at $10.0 million, down 71.01% from a year prior.
  • Revenue was $2.2 million for Q3 2025 at Caribou Biosciences, down from $2.7 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $23.7 million in Q3 2023 to a low of $1.5 million in Q2 2021.
  • A 5-year average of $4.0 million and a median of $2.7 million in 2025 define the central range for Revenue.
  • Peak YoY movement for Revenue: skyrocketed 616.38% in 2023, then tumbled 91.45% in 2024.
  • Caribou Biosciences' Revenue stood at $2.6 million in 2021, then skyrocketed by 44.28% to $3.7 million in 2022, then decreased by 3.63% to $3.6 million in 2023, then plummeted by 41.62% to $2.1 million in 2024, then rose by 5.83% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Revenue are $2.2 million (Q3 2025), $2.7 million (Q2 2025), and $2.4 million (Q1 2025).